US medicines with clinical-trial evidence for a new indication

52 of the 953 medicines with a UsTxGNN report have a TxGNN-predicted new indication graded at evidence level L1 or L2 (14 at L1, 38 at L2), meaning clinical-trial evidence (randomized trials, Phase 2–3 trials or systematic reviews) was found for it.

The medicines come from the FDA National Drug Code (NDC) Directory, with marketing status from Drugs@FDA shown in each drug report; the list reflects the drug reports as last updated on 2026-11-20.

Trial evidence for a predicted indication is not proof of efficacy. Every candidate below still requires clinical validation and regulatory review before any clinical use.

Medicines with trial evidence (L1–L2)

DrugPredicted new indicationEvidence levelRegistered trials cited (NCT)
Bendamustinemantle cell lymphomaL110
BromfenacEye diseaseL110
BupropionAttention deficit-hyperactivity disorderL16
BusulfanMyelodysplastic syndromeL110
Clofarabinemyeloid leukemiaL110
ClomipramineAnxiety disorderL1 (with caveat)8
DapsonePneumocystosisL110
NepafenacEye diseaseL111
Peginterferon Alfa-2AHepatitis E virus infectionL110
PlatinumUrinary bladder carcinomaL1 (with caveat)6
PolidocanolEsophageal varices with bleedingL1 (with caveat)0
PotassiumHypertensive disorderL1 (with caveat)7
RibavirinChronic hepatitis B virus infectionL1 (with caveat)10
TacrolimusSeborrheic dermatitisL12
Acetylcysteinethrombotic diseaseL27
Armodafinilinsomnia (disease)L23
AtorvastatinHIV infectious diseaseL210
BelinostatMyeloid leukemiaL2 (with caveat)6
Brentuximab VedotinFollicular lymphomaL2 (with caveat)6
Cefprozilurinary tract infection (disease)L20
CitalopramObsessive-compulsive disorderL24
ClozapineManic bipolar affective disorderL21
CyclobenzaprineMyofascial pain syndromeL2 (with caveat)10
DasatinibEwing sarcomaL2 (with caveat)2
DiazepamInsomnia (disease)L20
DocetaxelEwing sarcomaL28
DoxorubicinEwing sarcomaL210
EslicarbazepineMigraine disorderL2 (with caveat)1
FludarabinePlasma cell myelomaL210
GoserelinAmenorrheaL21
HydrocortisoneAlopecia areataL21
IdelalisibMantle cell lymphomaL2 (with caveat)5
KetamineHeadache disorderL2 (with caveat)9
LenalidomideMyeloid leukemiaL212
Mefenamic AcidHeadache disorderL20
MontelukastBronchitisL210
Mycophenolate MofetilHIV infectious diseaseL2 (with caveat)4
NortriptylineAttention deficit-hyperactivity disorderL2 (with caveat)0
OfatumumabFollicular lymphomaL210
OxaliplatinMalignant pleural mesotheliomaL23
PazopanibLiposarcomaL26
PimecrolimusSeborrheic dermatitisL21
PrednisoloneAlopecia areataL20
PropofolMigraine disorderL23
RegorafenibLiposarcomaL21
RisankizumabDermatitisL22
Sodium OxybateInsomnia (disease)L23
SofosbuvirTop TxGNN prediction: hepatitis B virus infection (rank 1). Best-supported candidate after evidence review: hepatitis E virus infection (rank 2)L2 (with caveat)5
SolriamfetolAttention deficit-hyperactivity disorderL25
SucralfateDuodenogastric refluxL20
TizanidineMigraine disorderL21
UstekinumabDermatitisL26

How to read this list

  • Evidence level follows the site’s criteria: L1 = Multiple Phase 3 RCTs / systematic reviews; L2 = Single RCT or multiple Phase 2 trials. “(with caveat)” means the drug report qualifies the grade; read the note in the report before relying on it.
  • Predicted new indication is the main prediction shown in each drug report. Indications and contraindications already recorded in the TxGNN knowledge graph are excluded, but some predictions may still overlap an established use; the report explains this where it applies.
  • Registered trials cited counts the ClinicalTrials.gov (NCT) numbers cited in the drug report. Reports cite a selection of the trials found; 0 means the report cites no registered trial, and its literature evidence section shows the basis for the grade.
  • For all levels and the full method, see High Evidence (L1-L2), All Drugs and the methodology.

Disclaimer
This report is for academic research reference only and does not constitute medical advice. Always follow your physician's instructions; never adjust medication on your own. Any drug repurposing decision requires full clinical validation and regulatory review.

Reviewed by: 藥提醒科技有限公司 (yao.care)

This site uses Just the Docs, a documentation theme for Jekyll.